METTL3 and acute myeloid leukemia: One prominent example of interfering with RNA modifying enzymes as a therapeutic strategy is the methyltransferase 3 (METTL3, also called N6-adenosine-methyltransferase) inhibitor STM2457, which is under investigation for the treatment of acute myeloid leukemia (AML) [8].